Tonix Pharm Hldg Cor (TNXP) 5.78 $TNXP
Tonix Pharmaceuticals raises USD28.7m from public offering
M2 - Tue Feb 10, 6:28AM CST
Medicine company Tonix Pharmaceuticals Holding (NasdaqGM:TNXP) disclosed on Monday the completion of its public offering of 4.9m shares of its common stock.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock
GlobeNewswire - Mon Feb 09, 12:45PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 4,900,000 shares of its common stock. The shares were sold at the public offering price of $5.85 per share, bringing the aggregate gross proceeds from the offering to approximately $28.7 million, before deducting underwriting discounts and commissions and other offering expenses. Investors in the offering included Broadfin Capital LLC, Deerfield Management Company, L.P., Sabby Management LLC and others.
TNXP: 5.78 (-0.02)
Nasdaq stocks posting largest volume increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ADEP: 6.93 (-0.30), TFSC: 9.43 (+0.02), TNXP: 5.78 (-0.02), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HPJ: 5.71 (+0.16), PEGI: 27.81 (+0.34), SABR: 21.74 (-0.01), BPFH: 13.08 (+0.22), SBCP: 12.03 (+0.02), ENTR: 2.92 (unch), HTWO: 10.20 (-0.30), ACFC: 3.95 (+0.05), OHGI: 1.82 (-0.12)
Tonix Pharmaceuticals to Present at the BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 05, 10:01AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 17 Annual BIO CEO and Investor Conference in New York City. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on Tuesday, February 10 at 9:30 a.m. ET.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals prices public offering of common shares at USD5.85 per share
M2 - Thu Feb 05, 5:48AM CST
Pharmaceutical company Tonix Pharmaceuticals Holding (NasdaqGM:TNXP) said on Wednesday that it has priced a public offering of 4,900,000 shares of its common stock at USD5.85 per share.
TNXP: 5.78 (-0.02)
Tonix Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:05AM CST
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 7:15AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the pricing of an underwritten public offering of 4,900,000 shares of its common stock at a price of $5.85 per share. The company has also granted to the underwriters a 45-day option to acquire an additional 735,000 shares to cover overallotments in connection with the offering. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.7 million, assuming no exercise of the overallotment option. The offering is expected to close on February 9, 2015, subject to customary closing conditions.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:18PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TNXP: 5.78 (-0.02)
Tonix Shares Looking Attractive As Clinical Programs Advance Forward
Jason Napodano, CFA - at Seeking Alpha - Wed Jan 28, 9:00AM CST
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
GlobeNewswire - Thu Jan 15, 6:05AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced today that the first participant in the AtEase study, sponsored by Tonix to evaluate TNX-102 SL for post-traumatic stress disorder (PTSD), has received study medication.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference
GlobeNewswire - Wed Jan 14, 7:40AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the Eleventh Annual Noble Financial Capital Markets Investor Conference in Sandpiper Bay, FL. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on Tuesday, January 20 at 3:30 p.m. ET.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache
GlobeNewswire - Fri Jan 09, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has completed a Phase 1 safety, tolerability, and pharmacokinetic study of TNX-201, which is being developed for episodic tension-type headache. In this single ascending dose, placebo-controlled trial, TNX-201 was well-tolerated at all doses studied, and showed a dose-related increase in pharmacokinetic parameters. A Phase 2, double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of TNX-201 for the treatment of a single episodic tension-type headache will commence in the second quarter of 2015.
TNXP: 5.78 (-0.02)
Driving the Market: Special Research on Twitter, Frontline, CytRx, Tonix and American Electric
PR Newswire - Wed Jan 07, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Twitter (NYSE: TWTR), Frontline (NYSE: FRO), CytRx (NASDAQ: CYTR), Tonix (NASDAQ: TNXP), and American Electric (NYSE: AEP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AEP: 57.83 (-0.15), FRO: 2.96 (+0.07), TNXP: 5.78 (-0.02), CYTR: 2.96 (+0.23), TWTR: 48.50 (+0.55)
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
XENT: 23.06 (+0.46), EVOK: 5.41 (-0.10), SKUL: 10.82 (+0.29), SSO.TO: 7.81 (+0.16), TNXP: 5.78 (-0.02), MCUR: 11.19 (-0.65), SSRI: 6.26 (+0.13), ICPT: 209.12 (+7.12), EBIX: 23.80 (+0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Tonix Pharma to initiate fibromyalgia study after FDA OK's primary endpoint
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 6:20AM CST
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
GlobeNewswire - Tue Jan 06, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has received written guidance from the U.S. Food and Drug Administration (FDA) on its Phase 3 clinical study design for TNX-102 SL in fibromyalgia.
TNXP: 5.78 (-0.02)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 37.22 (+0.27), TNXP: 5.78 (-0.02), MRNS: 10.94 (-0.06), CPRX: 3.36 (-0.10), VNDA: 12.37 (unch), ITCI: 24.53 (+2.45), OMER: 20.63 (+0.13)
Tonix Pharmaceuticals to Present at the LD Micro Investor Conference
GlobeNewswire - Tue Nov 25, 7:40AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the LD Micro Main Event VII Conference in Los Angeles, CA. Seth Lederman, M.D., Tonix's chief executive officer, will deliver a corporate overview on Tuesday, December 2, 2014 at 8:00 a.m. PT (11:00 a.m. ET).
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals: Positive Developments In Third Quarter
Tyler Kaster - at Seeking Alpha - Wed Nov 12, 7:14AM CST
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals raises USD28.7m from public offering
M2 - Tue Feb 10, 6:28AM CST
Medicine company Tonix Pharmaceuticals Holding (NasdaqGM:TNXP) disclosed on Monday the completion of its public offering of 4.9m shares of its common stock.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock
GlobeNewswire - Mon Feb 09, 12:45PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 4,900,000 shares of its common stock. The shares were sold at the public offering price of $5.85 per share, bringing the aggregate gross proceeds from the offering to approximately $28.7 million, before deducting underwriting discounts and commissions and other offering expenses. Investors in the offering included Broadfin Capital LLC, Deerfield Management Company, L.P., Sabby Management LLC and others.
TNXP: 5.78 (-0.02)
Nasdaq stocks posting largest volume increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ADEP: 6.93 (-0.30), TFSC: 9.43 (+0.02), TNXP: 5.78 (-0.02), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HPJ: 5.71 (+0.16), PEGI: 27.81 (+0.34), SABR: 21.74 (-0.01), BPFH: 13.08 (+0.22), SBCP: 12.03 (+0.02), ENTR: 2.92 (unch), HTWO: 10.20 (-0.30), ACFC: 3.95 (+0.05), OHGI: 1.82 (-0.12)
Tonix Pharmaceuticals to Present at the BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 05, 10:01AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 17 Annual BIO CEO and Investor Conference in New York City. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on Tuesday, February 10 at 9:30 a.m. ET.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals prices public offering of common shares at USD5.85 per share
M2 - Thu Feb 05, 5:48AM CST
Pharmaceutical company Tonix Pharmaceuticals Holding (NasdaqGM:TNXP) said on Wednesday that it has priced a public offering of 4,900,000 shares of its common stock at USD5.85 per share.
TNXP: 5.78 (-0.02)
Tonix Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:05AM CST
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 7:15AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the pricing of an underwritten public offering of 4,900,000 shares of its common stock at a price of $5.85 per share. The company has also granted to the underwriters a 45-day option to acquire an additional 735,000 shares to cover overallotments in connection with the offering. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.7 million, assuming no exercise of the overallotment option. The offering is expected to close on February 9, 2015, subject to customary closing conditions.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:18PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TNXP: 5.78 (-0.02)
Tonix Shares Looking Attractive As Clinical Programs Advance Forward
Jason Napodano, CFA - at Seeking Alpha - Wed Jan 28, 9:00AM CST
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
GlobeNewswire - Thu Jan 15, 6:05AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced today that the first participant in the AtEase study, sponsored by Tonix to evaluate TNX-102 SL for post-traumatic stress disorder (PTSD), has received study medication.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference
GlobeNewswire - Wed Jan 14, 7:40AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the Eleventh Annual Noble Financial Capital Markets Investor Conference in Sandpiper Bay, FL. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on Tuesday, January 20 at 3:30 p.m. ET.
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache
GlobeNewswire - Fri Jan 09, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has completed a Phase 1 safety, tolerability, and pharmacokinetic study of TNX-201, which is being developed for episodic tension-type headache. In this single ascending dose, placebo-controlled trial, TNX-201 was well-tolerated at all doses studied, and showed a dose-related increase in pharmacokinetic parameters. A Phase 2, double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of TNX-201 for the treatment of a single episodic tension-type headache will commence in the second quarter of 2015.
TNXP: 5.78 (-0.02)
Driving the Market: Special Research on Twitter, Frontline, CytRx, Tonix and American Electric
PR Newswire - Wed Jan 07, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Twitter (NYSE: TWTR), Frontline (NYSE: FRO), CytRx (NASDAQ: CYTR), Tonix (NASDAQ: TNXP), and American Electric (NYSE: AEP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AEP: 57.83 (-0.15), FRO: 2.96 (+0.07), TNXP: 5.78 (-0.02), CYTR: 2.96 (+0.23), TWTR: 48.50 (+0.55)
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
XENT: 23.06 (+0.46), EVOK: 5.41 (-0.10), SKUL: 10.82 (+0.29), SSO.TO: 7.81 (+0.16), TNXP: 5.78 (-0.02), MCUR: 11.19 (-0.65), SSRI: 6.26 (+0.13), ICPT: 209.12 (+7.12), EBIX: 23.80 (+0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Tonix Pharma to initiate fibromyalgia study after FDA OK's primary endpoint
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 6:20AM CST
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
GlobeNewswire - Tue Jan 06, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has received written guidance from the U.S. Food and Drug Administration (FDA) on its Phase 3 clinical study design for TNX-102 SL in fibromyalgia.
TNXP: 5.78 (-0.02)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 37.22 (+0.27), TNXP: 5.78 (-0.02), MRNS: 10.94 (-0.06), CPRX: 3.36 (-0.10), VNDA: 12.37 (unch), ITCI: 24.53 (+2.45), OMER: 20.63 (+0.13)
Tonix Pharmaceuticals to Present at the LD Micro Investor Conference
GlobeNewswire - Tue Nov 25, 7:40AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the LD Micro Main Event VII Conference in Los Angeles, CA. Seth Lederman, M.D., Tonix's chief executive officer, will deliver a corporate overview on Tuesday, December 2, 2014 at 8:00 a.m. PT (11:00 a.m. ET).
TNXP: 5.78 (-0.02)
Tonix Pharmaceuticals: Positive Developments In Third Quarter
Tyler Kaster - at Seeking Alpha - Wed Nov 12, 7:14AM CST
TNXP: 5.78 (-0.02)
